Target Validation Information
TTD ID	T08856
Target Name	Matrix metalloproteinase-8 (MMP-8)
Type of Target	Clinical trial
Drug Potency against Target	Marimastat	Drug Info	IC50 = 2 nM	[9]
	2-(biphenyl-4-ylsulfonamido)pentanedioic acid	Drug Info	IC50 = 1024 nM	[7]
	2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	Drug Info	IC50 = 1000 nM	[8]
	3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol	Drug Info	IC50 = 585 nM	[1]
	3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol	Drug Info	IC50 = 1100 nM	[1]
	3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol	Drug Info	IC50 = 8 nM	[1]
	3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol	Drug Info	IC50 = 4 nM	[1]
	4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid	Drug Info	IC50 = 670 nM	[7]
	BB-1101	Drug Info	IC50 = 3 nM	[3]
	CIPEMASTAT	Drug Info	IC50 = 7 nM
	CIPEMASTAT	Drug Info	Ki = 4 nM	[4]
	GM6001	Drug Info	Ki < 1 nM
	IK-862	Drug Info	Ki = 257 nM	[6]
	MMI270	Drug Info	IC50 = 4.4 nM	[2]
	N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	Drug Info	IC50 = 620 nM	[8]
	Ro-37-9790	Drug Info	IC50 = 4.9 nM
	SC-44463	Drug Info	Ki = 0.7 nM	[5]
	[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	Drug Info	IC50 = 290 nM	[8]
References
REF 1	Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.
REF 2	Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. J Med Chem. 1999 Nov 4;42(22):4547-62.
REF 3	New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors. J Med Chem. 1999 Nov 18;42(23):4890-908.
REF 4	Protease inhibitors: current status and future prospects. J Med Chem. 2000 Feb 10;43(3):305-41.
REF 5	Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivati... J Med Chem. 2001 Oct 11;44(21):3347-50.
REF 6	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
REF 7	Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8.
REF 8	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
REF 9	Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. Curr Pharm Des. 2005;11(3):295-322.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.